

Commencement of Medicinal Cannabis Product Licensing Applications

The Board of Impression Healthcare Limited (“Impression” or the “Company”) is pleased to announce that it has commenced the application process to obtain licences from the State Department of Health, Victoria and the Federal Office of Drug Control (“ODC”) for the importation, storage, distribution and export of medicinal cannabis products.

The application process follows Impression’s announcement on the 23rd of September 2018 in relation to a collaboration with leading cannabinoid therapeutics company, AXIM Biotechnologies Inc (“AXIM”). For more information on the collaboration with AXIM, please see the following ASX announcement previously released by the Company: <https://www.asx.com.au/asxpdf/20180919/pdf/43yfycrg879kk8.pdf>

The licenses being pursued will allow Impression, subject to individual product permit issue, the capacity to capitalise on local and international opportunities by importing and exporting a wide range of therapeutic cannabis products to generate cash flow. It is intended that imported products be saleable under the Special Access Schemes and Authorised Prescriber Network, as regulated under the Therapeutic Goods Administration. The procurement of an export license is consistent with the Company’s strategy of progressive and selective international expansion, with sales of the Company’s existing product, the Knight Guard, having commenced in New Zealand.

The application process is being completed in conjunction with the Company’s cannabis consultants. And, Impression expects to have the license and additional security protocols in place at its Melbourne-based laboratory and manufacturing facility by the first quarter of 2019.

ENDS



Date: 24 October 2018
ASX Announcement (ASX: IHL)

About Impression Healthcare Limited (ASX: IHL)

Impression Healthcare Limited is Australia's largest home dental impression company and is disrupting the dental devices market by providing consumers with an in-home method to consume laboratory-grade and personalised dental healthcare products at significantly lower prices than those offered by the traditional dental industry. Impression has significantly grown its distribution footprint and increased its revenues by 359% in the 2018 Financial Year. With its own dental laboratory in Victoria, Australia Impression offers best in class teeth protection and helps its customers combat bruxism, snoring, mild to moderate sleep apnoea and teeth discolouration with custom-fitted oral devices.

Impression is broadening its commitment to disruption in the healthcare sector by exploring opportunities in medicinal cannabis distribution and development, underpinned by a collaboration agreement with leading US Cannabinoid therapeutics Company, AXIM Biotechnologies Inc. AXIM is focused on research, development and production of oral health, pharmaceutical, nutraceutical and cosmetic products incorporating cannabinoids for a wide range of indications. Impression will leverage its oral health marketing activities to explore opportunities distribute a range of AXIM's over the counter and therapeutic products as public opinion of cannabinoid-based therapeutics steadily improves.

Investors: investors@impression.healthcare

Website: www.impression.healthcare